Novavax, Inc. (NVAX)
8.90
+0.34
(+3.97%)
USD |
NASDAQ |
Jun 11, 14:37
Novavax PS Ratio : 2.493 for June 11, 2026
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| June 10, 2026 | 2.397 |
| June 09, 2026 | 2.428 |
| June 08, 2026 | 2.414 |
| June 05, 2026 | 2.658 |
| June 04, 2026 | 2.854 |
| June 03, 2026 | 2.856 |
| June 02, 2026 | 2.859 |
| June 01, 2026 | 2.943 |
| May 29, 2026 | 3.072 |
| May 28, 2026 | 2.890 |
| May 27, 2026 | 3.106 |
| May 26, 2026 | 2.929 |
| May 22, 2026 | 2.579 |
| May 21, 2026 | 2.515 |
| May 20, 2026 | 2.596 |
| May 19, 2026 | 2.492 |
| May 18, 2026 | 2.501 |
| May 15, 2026 | 2.537 |
| May 14, 2026 | 2.618 |
| May 13, 2026 | 2.585 |
| May 12, 2026 | 2.694 |
| May 11, 2026 | 2.660 |
| May 08, 2026 | 2.831 |
| May 07, 2026 | 2.585 |
| May 06, 2026 | 2.621 |
| Date | Value |
|---|---|
| May 05, 2026 | 2.268 |
| May 04, 2026 | 2.249 |
| May 01, 2026 | 2.252 |
| April 30, 2026 | 2.219 |
| April 29, 2026 | 2.232 |
| April 28, 2026 | 2.218 |
| April 27, 2026 | 2.26 |
| April 24, 2026 | 2.302 |
| April 23, 2026 | 2.282 |
| April 22, 2026 | 2.366 |
| April 21, 2026 | 2.378 |
| April 20, 2026 | 2.428 |
| April 17, 2026 | 2.476 |
| April 16, 2026 | 2.420 |
| April 15, 2026 | 2.434 |
| April 14, 2026 | 2.350 |
| April 13, 2026 | 2.271 |
| April 10, 2026 | 2.274 |
| April 09, 2026 | 2.392 |
| April 08, 2026 | 2.358 |
| April 07, 2026 | 2.235 |
| April 06, 2026 | 2.232 |
| April 02, 2026 | 2.156 |
| April 01, 2026 | 2.246 |
| March 31, 2026 | 2.280 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Merck & Co., Inc. | 4.663 |
| Pfizer Inc. | 2.367 |
| AbbVie, Inc. | 6.402 |
| Amgen, Inc. | 5.179 |
| Fate Therapeutics, Inc. | 36.05 |
PS Ratio Related Metrics
| Price | 8.90 |
| Earnings Yield | -6.71% |
| Market Cap | 1.463B |
| Operating PE Ratio | 39.94 |
| Normalized PE Ratio | 1155.84 |